anonymous
Guest
anonymous
Guest
i think that there is way over-analysis going on here. The mortality benefit spin by Medical Affairs is nice cover, but in the prescriber trenches they dont give a damn. Its all about cheap access and low copays with no callbacks from pharmacists and angry patients. GSK wont budge an inch, and we have a BID med here, with an arguably good pMDI format, but many prefer dry powder. So we either simply cannibalize our existing SYMBICORT business, or roll over and give up and head to the bar for martinis and laughs. Bevespi is a bad joke by now, but at least we should have learned something from that fiasco. But I can convert most of my SYMBICORT business like a charm. So let's hear it, what do we do? How about it Dominator?